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Despite the existence of several effective drugs for chronic tophaceous gout, management is often
neither rational nor effective. Wendy Lipworth and colleagues examine the possible reasons
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An evidence based or “rational” approach to prescribing is
thought to maximise the benefit and minimise the harm from
prescription drugs. Unfortunately, prescribing often does not
meet this ideal despite clinicians’ best intentions. We use
treatment of chronic tophaceous gout to show how apparently
irrational prescribing arises from several interacting “failures”
in both clinical practice and drug development.
Treatment of chronic gout
Chronic tophaceous gout is the most common inflammatory
arthritis in older men and affects about 1-2% of adults in the
developed world.1 For most patients, allopurinol—a xanthine
oxidase inhibitor that blocks the synthesis of uric acid—is highly
effective in preventing recurrent attacks of acute gout and the
development of chronic tophaceous gout.2 Allopurinol is easy
to administer (generally requiring only a once daily dose),
inexpensive, and generally well tolerated aside from the
extremely rare, and sometimes predictable, allopurinol
hypersensitivity reaction and other more common but generally
minor or controllable adverse reactions.3-5
It seems, therefore, that allopurinol should be the mainstay for
prevention and management of chronic gout and that this
condition should be well controlled in the population. But in
reality, many patients are prescribed subtherapeutic doses of
allopurinol (usually ≤300 mg daily compared with a maximum
of 800 mg approved by the US Food and Drug Administration
for patients with normal renal function) and fewer than half of
patients receive allopurinol for more than a year despite needing
continuing prophylaxis.6-8 Similarly, there is underuse of
probenecid, a uricoscuric that is a safe, inexpensive, and
effective alternative to allopurinol for patients who do not have
a history of nephrolithiasis or serious renal impairment.9-11
There are several possible reasons for this underprescribing of
allopurinol and probenecid, some of which relate to clinical
practice and some to the drug development process.
Failure of clinical practice?
The most obvious clinical reason for underuse of allopurinol
would be that clinicians are concerned about allopurinol
hypersensitivity syndrome, particularly in otherwise healthy
patients. But given the low incidence of the syndrome, this is
unlikely to be the sole explanation.
Another possible reason for undertreatment is that the doctors
who manage chronic gout are often not specialist
rheumatologists12 andmight not always recognise gout or realise
the importance of treating both acute and chronic disease (acute
gout is also often poorly managed).13 Lack of knowledge about
the appropriate treatment might arise because clinicians receive
limited education about older (off-patent) therapies or because
general physicians are unfamiliar with guidelines developed by
specialist organisations and published in specialist journals.14
Thus, clinicians might be unfamiliar with the correct protocols
for using uricosuric drugs7 and might make oversimplistic
correlations between plasma urate concentrations and treatment
success.15 16 Oversimplistic interpretation of early studies of
allopurinol might also lead non-specialists to overestimate the
frequency of allopurinol hypersensitivity syndrome,17 and they
might not know that it can be preventable or that allopurinol
can be used in patients with chronic kidney disease without
necessarily limiting the maximum dose.18 Similarly, clinicians
might be unaware that probenecid can be used safely in most
patients provided the dose is increased slowly and patients are
well hydrated.
Underprescribing could also be a consequence of the many well
recognised barriers to rational prescribing, including habit, lack
of motivation, and external barriers such as lack of time,
resources, and organisational support.19 Furthermore, in the case
of chronic gout, the problem of poorly managed, treatment
induced flares could lead to poor patient adherence and a
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reluctance to prescribe.20 Compliance with prophylaxis might
also be undermined by the stigma attached to the disease.21
Failure of drug development?
But suboptimal treatment of chronic gout is not only the result
of failure in clinical practice. Given that prescribing is only as
rational as the evidence on which it based, we also need to
consider the role of the drug development process.
The development of new drugs, although providing benefits for
a small subset of patients, might not contribute much to the
overall disease burden of chronic tophaceous gout and might
carry considerable cost. One such example is febuxostat, a
non-purine xanthine oxidase inhibitor approved by the European
Medicines Agency in 2008 and by the FDA in 2009. On the
face of it, there is nothing wrong with developing additional
drugs for people who cannot use existing treatments. But new
drugs like febuxostat (which is considerably more expensive
than allopurinol) can easily become preferentially prescribed
without a robust rationale or sufficient knowledge of long term
safety—a concern with febuxostat, for which further data are
needed on cardiovascular safety and hypersensitivity.
In gout, febuxostat might be prescribed more often than
necessary partly because the judgment that a patient has “failed
to respond” to allopurinol is highly subjective and could be
made in patients with suboptimal dosing or because of an
“irrational” fear or misdiagnosis of hypersensitivity syndrome.4
Furthermore, trials supporting the registration of febuxostat
compared therapeutic doses of febuxostat to subtherapeutic
(albeit commonly prescribed) doses of allopurinol, and therefore
the relative efficacy of febuxostat could have been
overestimated.22 The drug industry’s interest in promoting a
patented and costly new product, and the enthusiastic and
relatively uncritical endorsement of febuxostat by many clinical
leaders,23 is likely to have further eroded the (appropriate) use
of allopurinol and probenecid.
Another reason for concern about the adequacy of drug
development processes surrounds the withdrawal from the
market of benzbromarone, a potent, long acting uricosuric drug
that was at least as effective as allopurinol and probenecid and
was suitable for patients with mild to moderate renal
impairment.9 Sanofi-Synthélabo withdrew the drug from the
European market in 2003, on the eve of its loss of patent
protection, citing reports of serious liver reactions. However,
benzbromarone had been associated with very few cases of
hepatotoxicity and some of the reported cases might have had
other contributing factors.4 Benzbromarone is now available
(from generic manufacturers) in only some markets and under
special access arrangements in other countries—this situation
may not be in the best interests of patients with gout given the
limited alternatives for patients with renal impairment who do
not tolerate allopurinol.4
The US approach to licensing colchicine is also a concern.
Colchicine is used primarily to treat acute gout but is also used
in chronic gout to prevent the flares that can occur when urate
lowering therapy is started. In October 2009, the FDA gave
URL Pharma three years of market exclusivity on the basis it
had shown that a lower dose regimen of colchicine (Colcrys)
was as effective as, and safer than, the higher dose regimen
recommended for the existing drug.24 This was an important
clinical finding but came at a price—the new patented
formulation is more than 50 times more expensive than the older
one (which is no longer available in the US). As Kesselheim
and Solomon have noted, the “curious case of colchicine” shows
“important limitations of our current system for rewarding
innovation in the pharmaceutical market.”25
Complex care in a complex environment
Taken together this leaves us in a situation that is indeed
“curious.” Firstly, we have two drugs (allopurinol and
probenecid) that, when used appropriately, are effective,
inexpensive, and safe but are repeatedly underprescribed.
Secondly, we have a far more expensive “alternative”
(febuxostat), which has a place for the few people who cannot
tolerate allopurinol or the uricosurics but is probably being used
unnecessarily. Thirdly, we have lost benzbromarone, which was
a safe alternative to allopurinol, probenecid, and febuxostat.
And finally, we have granted a patent to a company for a drug
(colchicine) that had been available off-patent for over half a
century.
Although gout provides an excellent illustration of the potential
for both clinical and regulatory forces to militate against rational
prescribing, this is in no way a unique situation. The underuse
of warfarin to prevent stroke in patients with atrial fibrillation
is another case in point: the evidence of benefit is strong, but
undertreatment persists for a number of reasons including lack
of conviction about benefit, concerns about side effects, and
inconvenience.26 At the same time, several new oral
anticoagulants are being licensed (and heavily promoted to both
doctors and patients) that have advantages over warfarin (such
as not requiring monitoring) but also have disadvantages (such
as being irreversible and more expensive).27 Another example
is the treatment of alcohol dependence, for which supervised
disulfiram is effective but has been largely displaced by more
expensive drugs.28 Many other underprescribed (or otherwise
misused) medicines are subject to similar complex forces.
Clearly neither clinicians nor drug developers are exclusively
responsible for this unsatisfactory state of affairs. Ultimately,
however, the case of chronic tophaceous gout provides a warning
that both clinical leaders and regulators must act to ensure that
the drug development process actually facilitates rational
prescribing and that new drugs are used appropriately. Possible
strategies that might facilitate better development and use of
medicines include developing better mechanisms for
comparative effectiveness and cost effectiveness research;
enhancing clinical leadership and finding better ways of
disseminating unbiased information to clinicians (particularly
to non-specialists) and patients; and providing clinicians with
feedback about their prescribing practices.
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